Cardiome Pharma Corp, a specialty pharmaceutical company,  announced that its partner, SteadyMed Therapeutics, successfully completed a clinical study of Trevyent with a press release discussing the study on April 5, 2017. Cardiome licensed the commercial rights to Trevyent from SteadyMed for many international markets in 2015.

SteadyMed's clinical validation study enrolled 60 healthy adult volunteers in an in-clinic setting designed to examine the performance of the PatchPump used by Trevyent. Each trial subject was provided one PatchPump device containing a placebo formulation and each otherwise carried on with their normal daily and nighttime routines over a 48 hour period. The goals of the study were to evaluate the safety and performance functions of the PatchPump delivery system as well as the tolerability of the on-body application of the product. According to SteadyMed, the results "indicate that the PatchPump devices performed as intended in all categories of evaluation", including dose accuracy and precision.

Commenting on SteadyMed's update, Hugues Sachot, Cardiome's senior VP Commercial, said "We continue to be pleased with the progress of our partnership with SteadyMed. We licensed Trevyent because we believed that there was a better way to deliver treprostinil to patients suffering from pulmonary arterial hypertension, and we remain convinced that Trevyent will provide just that."

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. PAH worsens over time and is life-threatening because the pressure in a patient's pulmonary arteries rises to dangerously high levels, putting a strain on the heart. There is no cure for PAH, but several medications are available to treat symptoms, such as the market-leading prostacyclin PAH therapy, Remodulin (treprostinil sodium), which is produced by United Therapeutics Corporation. The annual cost of Remodulin is reported to be between approximately $125,000 and $175,000 per patient and United Therapeutics reported Remodulin revenues of $602 million in 2016.

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of patients suffering from disease.